Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-chou, Aoba-ku, Sendai, 980-8574, Japan.
Esophagus. 2022 Oct;19(4):653-659. doi: 10.1007/s10388-022-00938-1. Epub 2022 Jul 2.
To evaluate the benefit of concurrent chemotherapy with radiotherapy (RT) for esophageal cancer in Asian patients aged ≥ 80 years using the Surveillance, Epidemiology, and End Results (SEER) database.
Among more than 7000 patients with squamous cell carcinoma or adenocarcinoma who were treated by RT without surgery for esophageal cancer in the SEER database, 2047 patients aged ≥ 80 years were analyzed. Patients who received chemoradiotherapy (CRT group) and patients who received RT alone (RT alone group) were matched with a propensity score.
The median observation period for survivors was 57 months. The 3-year and 5-year overall survival rates in all patients were 15.2% and 8.5%, respectively. The 3-year and 5-year cause-specific survival rates in all patients were 20.8% and 14.5%, respectively. After propensity score matching, the overall survival rate in the CRT group was significantly higher than that in the RT alone group (5-year overall survival rates: 11.9% and 3.2%, respectively, p < 0.001). In 108 Asian or Pacific Islander patients, there was no significant difference (5-year overall survival rates: 13.5% and 0%, respectively, p = 0.291), although the overall survival rate in the CRT group was significantly higher than that in the RT alone group in any other race.
It is controversial whether CRT is beneficial for Asian or Pacific Islander patients aged 80 years or older with esophageal cancer based on Analysis of data in SEER database.
利用监测、流行病学和最终结果（SEER）数据库评估同步放化疗（RT）对年龄≥80 岁亚洲食管癌患者的益处。
在 SEER 数据库中，对 7000 多名未接受手术治疗的食管鳞状细胞癌或腺癌患者进行了 RT 治疗，其中 2047 名年龄≥80 岁的患者被分析。接受放化疗（CRT 组）和单独接受 RT（单独 RT 组）的患者进行了倾向评分匹配。
生存者的中位观察期为 57 个月。所有患者的 3 年和 5 年总生存率分别为 15.2%和 8.5%，3 年和 5 年特异性生存率分别为 20.8%和 14.5%。经过倾向评分匹配后，CRT 组的总生存率显著高于单独 RT 组（5 年总生存率分别为 11.9%和 3.2%，p<0.001）。在 108 名亚洲或太平洋岛民患者中，两组之间没有显著差异（5 年总生存率分别为 13.5%和 0%，p=0.291），尽管 CRT 组的总生存率明显高于单独 RT 组的任何其他种族。
基于 SEER 数据库数据分析，对于年龄≥80 岁的亚洲或太平洋岛民食管癌患者，CRT 是否有益尚存争议。
